Findings

What do systematic reviews say?

21 questions · 21 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 4.8%Low 10 · 47.6%Moderate 10 · 47.6%High 0 · 0%

Budesonide MMX® 9 mg vs placebo

Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 2.25 [1.5, 3.39]
3 studies · 900 participants
Moderate

Budesonide MMX® 9 mg vs placebo

Clinical improvement · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.3 [0.99, 1.7]
2 studies · 442 participants
Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in remission (combined clinical and endoscopic remission) compared with entocort EC 9mg (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.38 [0.72, 2.65]
1 study · 212 participants
Low

Budesonide MMX® 9 mg vs placebo

Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg probably leads to higher endoscopic improvement compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.29 [1.01, 1.66]
2 studies · 442 participants
Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Clinical improvement · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with entocort EC 9mg (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.28 [0.9, 1.82]
1 study · 212 participants
Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in endoscopic improvement compared with entocort EC 9mg (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.14 [0.82, 1.6]
1 study · 212 participants
Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Histologic remission · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in histologic remission compared with entocort EC 9mg (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.21 [0.64, 2.31]
1 study · 212 participants
Low

Budesonide MMX® 9 mg vs Entocort EC 9mg

Serious adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with entocort EC 9mg (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 3.94 [0.45, 34.74]
1 study · 254 participants
Low

Budesonide MMX® 9 mg vs Entocort EC 9mg

Adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in adverse events compared with entocort EC 9mg (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.01 [0.81, 1.26]
1 study · 254 participants
Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Withdrawals due to adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in withdrawal due to adverse events compared with entocort EC 9mg (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.94 [0.56, 1.58]
1 study · 254 participants
Moderate

Budesonide MMX® 9 mg vs placebo

Histologic remission · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg may leads to higher histologic remission compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.51 [1.11, 2.06]
3 studies · 900 participants
Low

Budesonide MMX® 9 mg vs placebo

Endoscopic remission · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg probably leads to higher endoscopic remission compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.56 [1.13, 2.16]
2 studies · 695 participants
Moderate

Budesonide MMX® 9 mg vs placebo

Serious adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.88 [0.33, 2.4]
2 studies · 513 participants
Low

Budesonide MMX® 9 mg vs placebo

Adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.09 [0.95, 1.26]
3 studies · 971 participants
Moderate

Budesonide MMX® 6 mg vs placebo

Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in endoscopic improvement compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.96 [0.73, 1.27]
2 studies · 440 participants
Moderate

Budesonide MMX® 6 mg vs placebo

Histologic remission · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in histologic remission compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.23 [0.63, 2.4]
2 studies · 440 participants
Low

Budesonide MMX® 6 mg vs placebo

Serious adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.63 [0.21, 1.91]
2 studies · 512 participants
Low

Budesonide MMX® 6 mg vs placebo

Adverse events · Adult patients with active ulcerative colitis

It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.13 [0.97, 1.32]
2 studies · 512 participants
Very low

Budesonide MMX® 6 mg vs placebo

Withdrawals due to adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.1 [0.55, 2.22]
2 studies · 512 participants
Low

Budesonide MMX® 6 mg vs placebo

Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in remission (combined clinical and endoscopic remission compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.8 [0.94, 3.42]
2 studies · 440 participants
Low